CyGenTiG · Project

Automated Light-Controlled Tissue Manufacturing to Replace Slow Manual Lab Work

healthPrototypeTRL 4Thin data (2/5)

cygentig.ethz.ch

Imagine building replacement body tissues the way a 3D printer builds objects — except instead of plastic, you're guiding living cells with precisely aimed light. Right now, growing tissues in the lab is like hand-painting every cell into place: painfully slow, inconsistent, and impossible to scale. CyGenTiG built a system where a computer watches cells through a camera, compares their growth to a blueprint, and shines light on exactly the right cells to steer them toward the desired tissue shape. Think of it as autopilot for tissue growing — the computer corrects course in real time so the tissue develops correctly without anyone touching it.

By the numbers

EUR 4,696,250

EU funding for technology development

Research partners in consortium

Countries involved (CH, DE, NL, UK)

Project deliverables produced

5.5 years

Project duration (Oct 2018 – Mar 2024)

The business problem

What needed solving

Building replacement tissues in the lab today is a manual, hands-on process — technicians physically guide cells through each growth step. This makes tissue production slow, expensive, and highly inconsistent from batch to batch. For any company trying to manufacture tissues at scale (whether for transplants, drug testing, or research), this manual bottleneck is the single biggest barrier to commercial viability.

The solution

What was built

CyGenTiG built a closed-loop tissue control system that uses light (optogenetics) guided by machine vision and computer modeling to automatically steer cell growth toward a planned tissue template. Key demonstrated output includes quantitative optical control of polarization and ureter production in renal organoids, validated across both 2D and 3D systems, with 20 deliverables produced over the project's lifetime.

Audience

Who needs this

Tissue engineering companies producing skin grafts, cartilage, or organ modelsPharma companies using organoid-based drug screening platformsBiotech equipment manufacturers building next-generation bioreactorsContract research organizations (CROs) offering tissue-based assay servicesAcademic medical centers with translational tissue engineering programs

Business applications

Who can put this to work

Regenerative medicine & tissue engineering

mid-size

Target: Companies developing lab-grown tissues, skin grafts, or organ models for transplant or drug testing

If you are a tissue engineering company dealing with high batch-to-batch variability and slow manual production — this project developed a closed-loop optical control system that uses machine vision to automatically guide cell growth toward a planned template. The system was demonstrated on renal organoids across both 2D and 3D cultures, pointing toward consistent, hands-off tissue production.

Pharmaceutical & drug discovery

enterprise

Target: Pharma companies using organoid models for drug screening and toxicity testing

If you are a pharma company spending weeks manually cultivating organ-on-chip models for drug screening — this project demonstrated automated optical control of renal organoid development. Consistent, reproducible organoid production could accelerate your screening pipeline and reduce the cost per tissue model. The consortium included 6 partners across 4 countries with EUR 4,696,250 in EU funding.

Biotech equipment & lab automation

mid-size

Target: Manufacturers of bioreactors, cell culture systems, and lab automation hardware

If you are a lab automation company looking for the next generation of cell culture control technology — this project combined machine vision, computer modeling, and optogenetic light delivery into a single closed-loop control platform. Integrating this technology into your bioreactor or culture systems could differentiate your product line with true real-time, cell-level control capabilities.

Frequently asked

Quick answers

What would it cost to license or adopt this technology?

Based on available project data, no pricing or licensing terms are disclosed. The project received EUR 4,696,250 in EU funding and was coordinated by a public university (Albert-Ludwigs-Universitaet Freiburg), so licensing would likely go through their technology transfer office. Early-stage university IP typically involves negotiated licensing fees.

Can this scale to industrial tissue production?

The project demonstrated the technology on renal organoids in both 2D and 3D systems, which is a meaningful proof of concept. However, this was a research project (FET Open funding) with 5 out of 6 partners being universities. Scaling to production volumes would require significant engineering and industrial validation beyond what was demonstrated.

Who owns the intellectual property?

IP is likely shared among the 6 consortium partners across 4 countries (CH, DE, NL, UK), with the coordinator Albert-Ludwigs-Universitaet Freiburg in Germany as the lead institution. Horizon 2020 rules generally allow each partner to own IP they generate. Contact the coordinator's technology transfer office for licensing discussions.

How does this compare to existing tissue engineering automation?

Most current tissue engineering relies on manual manipulation, which the project objective explicitly identifies as the key bottleneck — calling it inefficient, time-consuming, and labour-intensive with high variability. CyGenTiG's approach of combining optogenetics with real-time machine vision feedback is distinct in that it controls individual cells with light rather than physical manipulation.

What was actually demonstrated and tested?

The project produced 20 deliverables over its 5.5-year run. A key demonstration deliverable includes image sets and quantitative measurements of optical closed-loop control of polarization and ureter production in renal organoids. This confirms working proof-of-concept in a biologically relevant system.

Is this technology ready for regulatory approval?

Based on available project data, this is still at the research stage. FET Open projects target breakthrough science rather than near-market products. Any clinical application would need to go through standard regulatory pathways (FDA, EMA) for cell-based therapies, which typically takes years beyond the research phase.

Consortium

Who built it

The CyGenTiG consortium is heavily academic: 5 of 6 partners are universities, with just 1 industry partner (17% industry ratio). The consortium spans 4 countries — Switzerland, Germany, the Netherlands, and the United Kingdom — giving it strong European research coverage. Coordination by Albert-Ludwigs-Universitaet Freiburg, a major German research university, lends scientific credibility. However, for a business looking to adopt this technology, the low industry participation means the path from lab to product will require additional industrial partnerships and engineering investment. The EUR 4,696,250 EU investment over 5.5 years confirms substantial research depth, but commercialization will need a dedicated technology transfer effort.

ALBERT-LUDWIGS-UNIVERSITAET FREIBURGCoordinator · DE
HEINRICH-HEINE-UNIVERSITAET DUESSELDORFparticipant · DE
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICHparticipant · CH
WAGENINGEN UNIVERSITYparticipant · NL
THE UNIVERSITY OF EDINBURGHparticipant · UK

How to reach the team

Albert-Ludwigs-Universitaet Freiburg technology transfer office, Germany

Order a report on this consortium See ALBERT-LUDWIGS-UNIVERSITAET FREIBURG profile →

Next steps

Talk to the team behind this work.

Want an introduction to the CyGenTiG research team? SciTransfer can connect you with the right people and prepare a tailored briefing on how this technology fits your needs.

Order a report on this topic More in Health & Biomedical